Neogen Chemicals Q1 FY27 Results: Net Profit ₹17.1 Cr, Up 66.0% YoY
Neogen Chemicals Ltd reported revenue from operations of ₹250.3 Cr (+34.1% YoY) and net profit of ₹17.1 Cr (+66.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹17.1 Cr · +66.0% YoY
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
65 announcements with these filters
Neogen Chemicals Ltd reported revenue from operations of ₹250.3 Cr (+34.1% YoY) and net profit of ₹17.1 Cr (+66.0% YoY) for Q1 FY27.
Neogen Chemicals Ltd's MD, Dr. Harin Kanani, has pledged 33,38,250 equity shares with Axis Trustee Services Limited. This pledge creates an encumbrance on promoter holdings.
Neogen Chemicals Ltd increased the coupon rate on its ₹200 Crore NCDs from 10.50% to 11.00% following a credit rating downgrade.
Neogen Chemicals Ltd will hold a board meeting on July 24, 2026, to approve the Q1 FY27 financial results and discuss a potential fundraising proposal.
CRISIL Ratings downgraded credit ratings for Neogen Chemicals Limited and its subsidiary, Neogen Ionics Limited, citing project and insurance claim delays.
Neogen Chemicals received a Rs. 15 Crore insurance payment for its Dahej facility fire. Total claims received reach Rs. 155 Crore against recognized losses.
Neogen Chemicals disclosed the record date and payment date for interest on its listed NCDs. Interest will be paid on July 31, 2026.
Neogen Chemicals paid Rs.1.55 Cr interest on its NCDs for June 2026. The payment amounts to approximately ₹10.56 Crore.
Neogen Chemicals fixed June 15, 2026, as the record date for interest payments on its NCDs. Payment is scheduled for June 30, 2026, ensuring regulatory compliance.
Axis Mutual Fund sold a 1.46% stake in Neogen Chemicals via open market transactions. Its holding reduced to 4.04%, reflecting institutional profit-booking or portfolio rebalancing.
Neogen Chemicals paid ₹1.61 Crore in monthly interest for its listed NCDs on May 28, 2026. This confirms timely debt service compliance for investors.
Neogen Chemicals submitted its Annual Secretarial Compliance Report for FY2026. The document details historical non-compliance regarding director re-appointments and confirms that all associated exchange fines were paid.
Neogen reported Q4 FY26 revenue of ₹247 crore (+22% YoY) and EBITDA of ₹44 crore (+21% YoY). The company is transitioning towards a battery materials-led portfolio with massive capex in Pakhajan and Dahej.
Neogen delivered volume-led Q4 growth but faces significant execution hurdles as battery project costs ballooned by ₹250cr+ while timelines shifted to the right.
Neogen Chemicals reported Q4 FY26 consolidated revenue of ₹247 Crore, up 22% Y-o-Y. The Board recommended a ₹1 per share final dividend for the fiscal year.
Neogen Chemicals delivered strong Q4 FY26 results with consolidated revenue growing 22% YoY to ₹247cr. Strategy focuses on high-growth battery materials and agrochem segments.
Neogen Chemicals received an unmodified audit opinion for its FY2026 financial results. This confirmation from auditors validates the company's reported financial integrity for shareholders.
Neogen Chemicals submitted its security cover certificate for Rs. 200 Crore in NCDs. The audit confirms maintenance of required asset coverage for debenture holders.
Neogen Chemicals Ltd reported revenue from operations of ₹246.6 Cr (+21.6% YoY) and net profit of ₹11.4 Cr (+375.0% YoY) for Q4 FY26.
Neogen Chemicals approved FY26 audited results and recommended a Re. 1 per share final dividend. Revenue reached ₹855.49 Crore, demonstrating steady annual growth.
Neogen Chemicals recommended a final dividend of 0.1 per share for FY 2025-26. Shareholders will receive the payout following approval at the general meeting.
Neogen Chemicals will hold a board meeting on May 16, 2026. Directors will consider audited financial results and a final dividend recommendation.
Neogen Chemicals Limited submitted its annual disclosure for the centralized database of non-convertible debentures for FY 2025-26. The filing confirms timely interest payments on its ₹200 Crore NCD issue (ISIN: INE136S07013) listed on BSE. The instrument maintains a 'CRISIL A/Negative' credit rating.
Neogen Chemicals Limited has fixed May 16, 2026, as the record date and May 31, 2026, as the payment date for interest on its secured, listed, non-convertible debentures (ISIN: INE136S07013). This follows SEBI Listing Regulations for debt securities.
Dr. Harin Haridas Kanani, a promoter of Neogen Chemicals Limited, created a pledge on 13,19,083 equity shares (5% of paid-up capital) in favour of Axis Trustee Services Limited. The pledge facilitates fund raising by promoter group member Cadamba Solutions Private Limited from Avendus Structured Credit Fund III.
Dr. Harin Haridas Kanani, promoter of Neogen Chemicals Limited, created a pledge on 20,19,167 equity shares (7.65% of paid-up capital) in favour of Axis Trustee Services Limited. The pledge facilitates fundraising for Cadamba Solutions Private Limited, a promoter group member, from Avendus Structured Credit Fund III.
Neogen Chemicals Ltd successfully paid ₹1.56 Crore in interest and principal for its non-convertible debentures on April 28, 2026. This timely payment relates to the ₹200 Crore NCD issue and demonstrates the company's commitment to meeting its debt obligations.
Neogen Chemicals' subsidiary, Neogen Ionics Limited, will subscribe to a ₹100.11 Crore rights issue of its own subsidiary, Neogen Morita New Material Limited. The capital will fund a salt business acquisition, CAPEX, and OPEX requirements. The allotment is expected within 60 days, strengthening the group's position in the lithium-ion battery material space.
Neogen Chemicals Limited allotted 10,00,000 equity shares to promoter-group entity Cadamba Solutions Private Limited on a preferential basis for ₹161 Crore. The allotment constitutes 3.65% of the post-issue paid-up capital, strengthening the company's equity base.
Neogen Chemicals Ltd allotted 10,00,000 equity shares to promoter group member Cadamba Solutions Private Limited on a preferential basis. The transaction, valued at ₹161 Crore, was executed at ₹1,610 per share. This infusion increases the promoter group's stake and strengthens the company's capital base.